Last update Feb. 4, 2021
Suggestions made at e-lactancia are done by APILAM team of health professionals, and are based on updated scientific publications. It is not intended to replace the relationship you have with your doctor but to compound it. The pharmaceutical industry contraindicates breastfeeding, mistakenly and without scientific reasons, in most of the drug data sheets.
Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.
Thank you for helping to protect and promote breastfeeding.
φαινυλοβουταζόνη is Phenylbutazone in Greek.Is written in other languages:
M01AA01; M02AA01(ATC Code/s)
φαινυλοβουταζόνη is also known as
φαινυλοβουταζόνη belongs to these groups or families:
Main tradenames from several countries containing φαινυλοβουταζόνη in its composition:
|Oral Bioavail.||100 (derm: ≈ 0)||%|
|VD||0.17 ± 0.02||l/Kg|
|T½||70 (29 - 175)||hours|
Write us at firstname.lastname@example.org
e-lactancia is a resource recommended by Asociación Española de Bancos de Leche Humana of Spain
Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM
Non-steroidal anti-inflammatory drug (NSAID) derived from pyrazolone. It also has antipyretic and analgesic properties.
Effective in the treatment of almost all osteoarticular conditions. Due to its hematological toxicity, it should be reserved as a second-line drug when other drugs have failed.
Oral or topical cutaneous administration maximum one week.
Since the last update we have not found any published data on its excretion in breast milk.
Its pharmacokinetic data (high percentage of protein binding and low pKa) makes transfer into breastmilk in significant quantities unlikely.
Only negligible absorption was seen following application of phenylbutazone to the skin of humans (Aarbakke 1978). The dermatological use of phenylbutazone is compatible with breastfeeding.
Due to its serious possible side effects, it has been withdrawn from the market in many countries.
American Academy of Pediatrics: medication usually compatible with breastfeeding (AAP 2001).
Until there is further published data on this drug in relation to breastfeeding, known safer alternatives may be preferable, especially during the neonatal period and in cases of prematurity.